Bio Electrical Impedance Analysis to Monitor Fluid Status During Deresuscitation Strategy in Continuous Renal Replacement Therapy

Fluid Overload Clinical Trial

— UF BIA  

Official title:

Bio Electrical Impedance Analysis to Monitor Fluid Status During Deresuscitation Strategy in Continuous Renal Replacement Therapy: a Proof of Concept Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05160467
• Other study ID #: 532
• Status: Recruiting
• Start date: March 15, 2021
• Est. completion date: January 2022

Study information

• Verified date: January 2022
• Source: Hospices Civils de Lyon
• Contact: Martin RUSTE, Dr
• Phone: +33472118956
• Email: martin.ruste[@]chu-lyon.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Fluid overload is a poor prognostic factor in patients undergoing continuous renal replacement therapy in critical care. A strategy of active fluid removal by net ultrafiltration (UFnet) is one of the means to correct it. However, fluid overload is difficult to quantify: weight variations or cumulative fluid balance are easy to use but imprecise and not concordant markers, while reference methods such as isotope dilution are not adapted to daily practice. Bio electrical impedance analysis (BIA) is used to estimate body composition, including hydration. It is a non-invasive, rapid and painless measurement. It is commonly used in chronic intermittent haemodialysis to estimate dry weight and guide fluid removal, with a demonstrated impact on blood pressure control. This analysis is feasible in the ICU. Fluid overload as defined by BIA correlates with mortality, most notably in acute renal failure and during continuous renal replacement therapy. We routinely perform multifrequency segmental BIA (InBody S10, Seoul, Korea) in patients with fluid overload in our intensive care department. Since February 2021, we have implemented a protocol to systematically correct fluid overload by inducing negative fluid balance with UFnet in a manner appropriate to tissue perfusion. In this context, we systematically perform a BIA analysis on the day of the beginning of the fluid balance negativation and then every 48 hours during the first five days. We would like to evaluate the relevance of BIA monitoring in these patients by comparing it to other parameters of evaluation of the volume status usually used.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 23
• Est. completion date: January 2022
• Est. primary completion date: November 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age higher than 18
• Protocol directed deresucitation strategy with net ultrafiltration during continuous renal replacement therapy
• Bioelectrical impedance analysis available for the day of the initiation of the deresuscitation strategy and at day 5" -> "At least two bioelectrical impedance analysis available during the first 5 days of the initiation of the deresuscitation strategy".

Exclusion Criteria:

• Left ventricular assist device
• Patient opposition to the use of his health data
• Invalid bioelectrical impedance analysis
• Advanced directives to withhold or withdraw life-sustaining treatment

Related Conditions & MeSH terms

• Fluid Overload

Intervention

Diagnostic Test:
• Segmental multi-frequency bio electrical impedance analysis
A segmental (eight-polar) multi-frequency bio electrical impedance analysis (Inbody S10, Seoul, Korea) is carried out at the initiation of the deresuscitation strategy, at day 1, 3 and 5, in lying posture with touch type electrodes. Raw and derived parameters are recorded. The measurement is performed 5 times for the first measurement and then one time at day 1, 3 and 5. Measurement error is defined by the manufacturer as: reversed Impedance in different segment all between 5-500kHz; impedance over 50? in trunk, or over 700? in limb; sudden drop of impedance in trunk (more than 10?), or in limb (more than 50?). If it occurs, measurement is carried out three times maximum after solving potential technical issues to obtain a valid analysis.

Locations

Country	Name	City	State
France	Hôpital cardiologique Louis Pradel Groupe Hospitalier Est	Bron

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation coefficient between changes in extracellular water volume estimated by BIA and cumulative fluid balance between day 0 and day 5 (mL).	The extra cellular water is a volumetric value, given automatically by the InBody S10 device. The cumulative fluid balance at day 5 is the sum of the daily fluid balances between day 0 and day 5.; Definition of the fluid balance = inputs - outputs : Inputs = total cumulative volume of: parenteral medication; enteral and parenteral nutrition; maintenance fluid; blood products; fluid bolus therapy; Outputs = total cumulative volume of: diuresis; losses to drain; net ultra filtration	Coefficient correlation between the variation from day 0 to day 5 of extra cellular water and cumulative fluid balance